These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15765243)

  • 1. The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation.
    Legendre C; Beard SM; Crochard A; Lebranchu Y; Pouteil-Noble C; Richter A; Durand-Zaleski I
    Eur J Health Econ; 2005 Jun; 6(2):172-82. PubMed ID: 15765243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation.
    Tilden DP; Chapman J; Davey PJ; Solly ML; Crowley S
    Clin Transplant; 2004 Jun; 18(3):312-20. PubMed ID: 15142054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
    Mauskopf JA; Richter A; Annemans L; Maclaine G
    Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic value of valacyclovir prophylaxis in transplantation.
    Squifflet JP; Legendre C
    J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation.
    Reischig T; Kacer M
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):771-9. PubMed ID: 25252996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
    Reddy SP; Handa A; Tan L; Devaney A; Hughes D; Mason P; Friend PJ; Darby CR
    Transpl Int; 2003 Oct; 16(10):726-9. PubMed ID: 12827230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation.
    Legendre CM; Norman DJ; Keating MR; Maclaine GD; Grant DM
    Transplantation; 2000 Nov; 70(10):1463-8. PubMed ID: 11118091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aciclovir or ganciclovir universal prophylaxis of cytomegalovirus infection in liver transplantation: an economic analysis.
    Leong RW; Smith DW; Garas G; Beaman JM; Mitchell AW; Heath DI; House AK; Jeffrey GP
    Intern Med J; 2004 Jul; 34(7):410-5. PubMed ID: 15271175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model.
    Grant DM; Mauskopf JA; Bell L; Austin R
    Pharmacotherapy; 1997; 17(2):333-41. PubMed ID: 9085325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients.
    Toussaint ND; Tan MB; Nicholls K; Walker RG; Cohney SJ
    Nephrology (Carlton); 2011 Jan; 16(1):113-7. PubMed ID: 21175987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
    Emery VC; Sabin C; Feinberg JE; Grywacz M; Knight S; Griffiths PD
    J Infect Dis; 1999 Sep; 180(3):695-701. PubMed ID: 10438356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrum and treatment of cytomegalovirus disease in persons with AIDS.
    Spector SA
    J Int Assoc Physicians AIDS Care; 1996 May; 2(5):9-12, 15-22. PubMed ID: 11363539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients.
    Kielberger L; Bouda M; Jindra P; Reischig T
    Kidney Blood Press Res; 2012; 35(6):407-16. PubMed ID: 22584353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
    J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges.
    Puius YA; Snydman DR
    Curr Opin Infect Dis; 2007 Aug; 20(4):419-24. PubMed ID: 17609603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of CMV infection and disease in transplant patients. 27-29 February 2004.
    Razonable RR; Emery VC;
    Herpes; 2004 Dec; 11(3):77-86. PubMed ID: 15960905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
    Kacer M; Kielberger L; Bouda M; Reischig T
    Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.